Product description

Metformin is a preparation that affects the digestive system and metabolism. Antidiabetic preparation.

Indications for use

Type 2 diabetes in case of ineffectiveness of diet therapy and exercise regime, especially in patients with excess body weight:

• as monotherapy or as part of combined therapy in combination with other oral hypoglycemic agents or in combination with insulin for the treatment of adults;
• as monotherapy or as part of combination therapy with insulin for the treatment of children aged 10 years and older and adolescents.
• To reduce the complications of diabetes in adult patients with type 2 diabetes and excess body weight as a first-line preparation after ineffective diet therapy.

Сomposition

1 tablet contains 850 mg of metformin hydrochloride as a 100% substance;

auxiliary substances: sodium starch glycolate (type A), povidone, corn starch, magnesium stearate, colloidal anhydrous silicon dioxide; composition of the film shell: hypromellose, polyethylene glycol 6000, talc, titanium dioxide (E171), propylene glycol.

Contraindication

• hypersensitivity to metformin or to any other component of the medicinal product;
• any type of acute metabolic acidosis (eg, lactic acidosis, diabetic ketoacidosis);
• diabetic precoma;
• severe renal failure (glomerular filtration rate (GFR) < 30 ml/min);

Application method

Usually, the starting dose is 500 mg or 850 mg (Metformin, film-coated tablets, 500 mg or 850 mg) 2-3 times a day during or after meals.

After 10-15 days, the dose must be adjusted according to the results of measuring the level of glucose in the blood serum.

A slow increase in the dose helps to reduce side effects from the digestive tract.

Features of application

Patients need to adhere to a diet, a uniform intake of carbohydrates throughout the day. Overweight patients should continue to follow a low-calorie diet. It is necessary to regularly monitor the indicators of carbohydrate metabolism of patients.

pregnant

In preclinical studies, no adverse effects on pregnancy, embryo or fetal development, childbirth and postnatal development were found.

Children

Metformin should be used by children over 10 years of age and adolescents.

Drivers

Metformin monotherapy does not affect the speed of reaction when driving vehicles or other mechanisms, as the preparation does not cause hypoglycemia. However, caution should be exercised when using metformin in combination with other hypoglycemic agents (sulfonylureas, insulin, or meglitinides) due to the risk of hypoglycemia.

Overdose

When using the preparation in a dose of 85 g, the development of hypoglycemia was not observed. However, in this case, the development of lactic acidosis was observed. A significant overdose of metformin or associated risk factors can cause lactic acidosis.

Side effects

Metabolic disorders: lactic acidosis

From the side of the nervous system: taste disturbances.

From the side of the liver and biliary tract: impaired liver function indicators or hepatitis, which completely disappear after withdrawal of metformin.

From the side of the skin and subcutaneous tissues: skin reactions, including erythema, itching, urticaria.

Storage conditions

Store in the original packaging at a temperature not higher than 25°C. Keep out of the reach of children.